PRRX1 and gastric adenocarcinoma: These pan-cancer survival analyses indicated that PRRX1 expression was an adverse prognostic factor in patients with seven types of cancer (Figure 7A): adrenocortical carcinoma (ACC), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), stomach adenocarcinoma (STAD), thyroid carcinoma (THCA), and uveal melanoma (UVM).